Castle Biosciences Exceeds 2025 Revenue Guidance with Strong Core Product Growth
summarizeSummary
The preliminary results indicate robust operational performance, with full-year 2025 revenue projected to surpass previous guidance. The substantial increase in test reports for core products like DecisionDx-Melanoma and TissueCypher, coupled with the successful limited launch of AdvanceAD-Tx, suggests strong market adoption and expansion opportunities. The healthy year-end cash position further strengthens the company's financial outlook for future growth initiatives.
check_boxKey Events
-
Exceeded Revenue Guidance
2025 total revenue is expected to exceed $340 million, surpassing the previously guided range of $327-335 million.
-
Strong Core Product Growth
Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 37% for the full year 2025 and 42% in Q4 2025 year-over-year.
-
TissueCypher Volume Surge
TissueCypher Barrett's Esophagus test reports saw an 86% volume increase for the full year 2025 compared to 2024.
-
New Product Launch
AdvanceAD-Tx, a new test for atopic dermatitis, commenced a limited access launch in November 2025, with strong initial clinician adoption.
auto_awesomeAnalysis
The preliminary results indicate robust operational performance, with full-year 2025 revenue projected to surpass previous guidance. The substantial increase in test reports for core products like DecisionDx-Melanoma and TissueCypher, coupled with the successful limited launch of AdvanceAD-Tx, suggests strong market adoption and expansion opportunities. The healthy year-end cash position further strengthens the company's financial outlook for future growth initiatives.
在该文件披露时，CSTL的交易价格为$39.64，交易所为NASDAQ，所属行业为Industrial Applications And Services，市值约为$11.6亿。 52周交易区间为$14.59至$42.18。 这份文件被评估为积极市场情绪，重要性评分为8/10。